Beam Therapeutics (NASDAQ: BEAM) CLO sells 1,371 shares via 10b5-1 plan

Q: What insider transaction did BEAM report for Christine Bellon?

Beam Therapeutics reported that Chief Legal Officer Christine Bellon sold 1,371 shares of the company’s common stock on January 22, 2026 .

Q: At what price were the Beam Therapeutics (BEAM) shares sold?

The reported sale by Chief Legal Officer Christine Bellon was executed at a price of $34 per share for Beam Therapeutics common stock.

Q: How many BEAM shares does Christine Bellon own after the transaction?

Following the reported sale, Chief Legal Officer Christine Bellon beneficially owned 95,667 shares of Beam Therapeutics common stock in direct ownership form.

Q: What is Christine Bellon’s role at Beam Therapeutics (BEAM)?

According to the filing, Christine Bellon is an officer of Beam Therapeutics and serves as the company’s Chief Legal Officer .

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Beam Therapeutics Chief Legal Officer Christine Bellon sold 1,371 shares of Beam Therapeutics common stock at $34 per share on January 22, 2026, under a Rule 10b5-1 trading plan. After this planned sale, she directly beneficially owned 95,667 shares of the company’s common stock. The trading plan was adopted by the reporting person on September 16, 2025, indicating the sale was executed pursuant to a pre-arranged schedule rather than a discretionary, same-day decision.

Insider Trade Summary

Net Seller: 1,371 shares

Net Sell 1 txn

Insider Bellon Christine

Role Chief Legal Officer

Sold 1,371 shs ($47K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,371	$34.00	$47K

Holdings After Transaction: Common Stock — 95,667 shares (Direct)

Footnotes (1)

F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/26/2026 - 04:05 PM

FAQ

What insider transaction did BEAM report for Christine Bellon?

Beam Therapeutics reported that Chief Legal Officer Christine Bellon sold 1,371 shares of the company’s common stock on January 22, 2026.

At what price were the Beam Therapeutics (BEAM) shares sold?

The reported sale by Chief Legal Officer Christine Bellon was executed at a price of $34 per share for Beam Therapeutics common stock.

How many BEAM shares does Christine Bellon own after the transaction?

Following the reported sale, Chief Legal Officer Christine Bellon beneficially owned 95,667 shares of Beam Therapeutics common stock in direct ownership form.

Was the BEAM insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2025.

What is Christine Bellon’s role at Beam Therapeutics (BEAM)?

According to the filing, Christine Bellon is an officer of Beam Therapeutics and serves as the company’s Chief Legal Officer.

Is the BEAM insider transaction reported as direct or indirect ownership?

The Form 4 indicates that the shares involved in the transaction were held in direct (D) ownership by the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bellon Christine

(Last)

(First)

(Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/22/2026		S⁽¹⁾		1,371	D	$34	95,667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2025.

	By: /s/ Christine Bellon	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR